Founder Mode Oncology: Translating Personalised Neoantigen Vaccines from Bespoke to Scalable Systems
- From Maximal Diagnostics to Actionable Design: How multi-sample tumour sequencing (WES/RNA/Proteomics) and longitudinal data are translated into a constrained set of vaccine targets in real-world, often low–tumour mutational burden settings
- Epitope Selection as a Decision System: A practical framework for integrating neoantigen prediction algorithms, expression data, HLA binding, and tumour evolution using a structured “Epitope Board” that combines computational outputs with expert review
- Balancing Neoantigens and Tumour-Associated Antigens: Design strategies for combining patient-specific neoepitopes with validated shared antigens to improve target density and immune response in clinical settings where mutation burden is limited